Jubilant Biosys signs partnership with Pierre Fabre SA
The partnership will add to Jubilant Biosys' drug discovery and preclinical development capabilities in biologics and antibody…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Market
Ebglyss FDA approval intensifies competition in atopic dermatitis market: GlobalData
Eli Lilly’s Ebglyss enters the US market, poised to challenge established therapies like Dupixent and Adbry/Adtralza in the atopic…
Navigating the changing pharma landscape with innovation
Shelja Jose Kuruvilla, Head – Knowledge and Research, Vector Consulting Group underscores that the Indian pharma industry faces…
Funding in pharma falls in September 2024, reaches $189 mn
As per Traxcn.com funding falls 45 per cent from $346 million in August 2024
Biocon Biologics refinances $ 1.1 bn long-term debt through USD bonds and new syndicated facility
The Bonds are expected to be rated BB by both S&P and Fitch and will be listed on the Singapore Stock Exchange
Gilead Sciences signs licencing agreements with six companies to manufacture, commercialise…
Dr Reddy’s Laboratories, Emcure Pharma, Hetero Drugs and Mylan Labs (a subsidiary of Viatris), are among the six companies that…
Revenues to increase by 9-11 % for Indian pharma companies in FY2025: ICRA
Revenues estimated to increase by 9-11 per cent from the US market, and 7-9 per cent each from the European and the domestic…
Venus Remedies gets marketing authorisations for oncology drugs from Morocco, Philippines
Marketing approvals for bortezomib from Philippines and carboplatin from Morocco aims to enhance its presence in ASEAN, African…
Ind-Ra forecasts weak API prices and volume growth for India in FY25
Decline in raw material costs and forward integration into formulations business help mitigate impact on margins
Pharma sector set for 8-10 per cent revenue growth this fiscal
The resultant improvement in operating leverage along with easing pricing pressure in the US generics market will improve…
Atopic Dermatitis: A hotspot for innovation and investment opportunities, says GlobalData
With the growth in AD, investment opportunities seem to be exciting, and pharmaceutical companies could invest in the R&D of…
Radiopharmaceuticals for prostate cancer to go nuclear with $6.3 bn in sales by 2030
GlobalData analyst consensus forecast predicts the global revenue of Pluvicto to rise from $980 million in 2023 to $4.3 billion by…
Neovantage Innovation Parks secures a green loan for its life sciences real estate portfolio
The Neovantage Innovation Parks portfolio is set up as a joint venture (JV) between Ivanhoé Cambridge, the real estate group of…
Migraine market to reach $16.4 billion in 7MM by 2033, forecasts GlobalData
CGRP antagonists drive growth, but access and reimbursement barriers remain challenges
Surge in pharma funding observed in August 2024, reached $135 mn
As per Traxcn.com, an increase of 382 per cent was observed as funding rocketed from $28 mn in July
Emcure launches Arth, aims to alleviate symptoms of menopause
The product range is developed to alleviate common menopause symptoms such as hot flashes, night sweats, mood swings, and vaginal…
Indian Immunologicals unveils pediatric dose of indigenous Hepatitis A vaccine, Havisure
The Hepatitis A vaccine is available in both 0.5 ml and 1 ml dosage forms for pediatric and adult use, respectively